ReviewFrontiers in medicine2020
Osteoporosis in Rheumatoid Arthritis: Dangerous Liaisons.
Review in Frontiers in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 3 syntheses or guidelines pooled it, 133 citations in OpenAlex.
- The prevalence of osteoporosis in rheumatoid arthritis patient: a systematic review and meta-analysis.Scientific reports · 2022Pooled it
- First metatarsophalangeal joint arthrodesis/fusion: a systematic review of modern fixation techniques.Journal of foot and ankle research · 2022Pooled it
- Influence of Iguratimod on Bone Metabolism in Patients with Rheumatoid Arthritis: A Meta-analysis.International journal of clinical practice · 2022Pooled it
- Bone Health in Rheumatoid Arthritis: An Update.Current rheumatology reports · 2026Review
- Serum Sclerostin Correlates with ACPA Positivity in Post-Menopausal Women with Rheumatoid Arthritis: Data from a Cross-Sectional Case-Control Study in Greece.Mediterranean journal of rheumatology · 2026Article
- Flare risk after oral glucocorticoid bridging with methotrexate or intra-articular bridging with triple therapy in early rheumatoid arthritis.Journal of internal medicine · 2026Observational
- Low-Dose Methotrexate and Bone Health: Pathophysiological and Clinical Perspectives.Journal of clinical medicine · 2026Review
- Comorbidity patterns and health-related quality of life in a cohort of Australian women cancer survivors.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Osteoimmunology uncovered: How macrophages and biomaterials revolutionize bone healing.Materials today. Bio · 2026Review
- Article
- Association between osteoporosis knowledge and bone health in patients with autoimmune diseases: a cross-sectional study.Frontiers in medicine · 2026Article
- Evaluating disease activity scores and CBC-derived indices in relation to osteoporosis risk in rheumatoid arthritis: a cross-sectional analysis.Frontiers in immunology · 2026Article
- Investigating the relationship between osteoporosis and rheumatoid arthritis: prospective cohort study and genetic analyses.Therapeutic advances in musculoskeletal disease · 2026Article
- Dual effects of JAK vs TNF inhibitors on osteoporosis, fractures and mortality in rheumatoid arthritis: a real-world cohort study.Frontiers in immunology · 2026Article
- Which One Can Detect More Osteopenia and Osteoporosis in Rheumatoid Arthritis Patient? Dual-Energy X-Ray Absorptiometry (DXA) or Trabecular Bone Score (TBS).International journal of preventive medicine · 2026Article
- Prevalence and Predictors of Osteoporosis Among Saudi Patients with Rheumatoid Arthritis: A Single-Center Cross-Sectional Study.Open access rheumatology : research and reviews · 2026Article
- Comparison of the effects of denosumab and alendronate on fracture risk and bone metabolism in postmenopausal rheumatoid arthritis patients treated with oral glucocorticoids: A propensity score-matched retrospective cohort study.Therapeutic advances in musculoskeletal disease · 2026Article
- Apelin promotes RANKL‑mediated osteoclastogenesis by activating MAPK and NF‑κB pathways.Molecular medicine reports · 2026Article
- The potential involvement of FABP4 in rheumatoid arthritis-associated osteoporosis: a comprehensive bioinformatics analysis and experimental validation.Frontiers in immunology · 2026Article
- Celastrol suppresses bone destruction in rheumatoid arthritis by inhibiting ALOX5 expression in macrophages via the NF-κB pathway.Scientific reports · 2025Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis has been classically considered a comorbidity of rheumatoid arthritis (RA). However, recent advances in the pathogenesis of osteoporosis in RA have shown a close interplay between cells of the immune system and those involved in bone remodeling, introducing new actors into the classic route in which osteoclast activation is related to the RANK/RANKL/OPG pathway. In fact, the inflammatory state in early stages of RA, mediated by interleukin (IL)-1, IL-6, IL-8 and tumor necrosis factor (TNF)-α has the ability to activate and differentiate osteoclasts not only through their relationship with RANKL, but also through the Wnt/DKK1/sclerostin pathway, leading to bone loss. The role of synovial fibroblasts and activated T lymphocytes in the expression of the RANKL system and its connection to bone destruction is also depicted. In addition, autoantibodies such as rheumatoid factor and anti-citrullinated protein antibodies are other pathogenic mechanisms for the development of bone erosions and systemic osteoporosis in RA, even before the onset of arthritis. The aim of this review is to unravel the relationship between different factors involved in the development of osteoporosis in RA patients, both the classic factors and the most novel, based on the relationship of autoantibodies with bone remodeling. Furthermore, we propose that bone mineral density measured by different techniques may be helpful as a biomarker of severity in early arthritis patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.